

Att. Docket No.: REG 710-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

10/009,852

Applicant:

Papadopoulos, et al.

Date Filed:

December 6, 2001

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC

PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner:

Unknown

Group Art Unit:

1614

January 16, 2003

U.S. PATENT DOCUMENTS

Examiner <u>Initials</u>	Patent <u>Number</u>	Issue <u>Date</u>	Publication <u>Number</u>	Publication <u>Date</u>	Name
RKH	6,011,003	01/04/00			Charnock-Jones, et al.
RKH	5,712,380	01/27/98			Kendall, et al

FOREIGN PATENT DOCUMENTS

Examiner <u>Initials</u>	Document <u>Number</u>	<u>Date</u>	Country	Class/ <u>Date Subclass</u>	slation <u>No</u>
RKH	WO98/13071 ·	04/02/98	PCT		
RKH	WO97/44453	11/27/97	PCT	•	•
RKH	WO99/03996	01/28/99	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Terman, B. I., et al, "Identification of a new endothelial cell growth factor receptor tyrosine kinase", Oncogene (1991) 6:1677-1683

Terman, B.I., et al, "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", Biochem Biophys Res Comm (1992) 187(3):1579-1586

__ Tsutsumi, Y., et al, "PEGylation of interleukin-6 effectively increases its thrombopoietic potency", Thrombosis and Haemostasis (1997) 77(1):168-173

	· ·						
PKH	_ Dunca, R. and Spreafico, F., "Polymer Conjugates", Drug Delivery Systems (1994) 27(4):290-306						
-	Hileman, R.E., et al., "Glycosaminoglycan-protein interactions: definitions of consensus sites in glycosaminoglycan binding proteins", BioEssays (1998) 20:156-167						
_	deVries, Carlie, et al., "The fins-like tyrosine kinase, a receptor for vascular endothelial growth factor", Science (1992) 225:989-991						
	Sharifi, J., et al., "Improving monoclonal antibody pharmacokinetics via chemical modification", Quart J Nucl Med (1998) 42:242-249						
	Jensen-Pippo, K.E., et al., "Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)", (1996) Pharm Res 13(1):102-107						
	Tanaka, K., et al., "Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 Tyrosine kinase)", (1997) Jpn J Cancer Res 88:867-876						
RKY	Yang, J.C., et al., "The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma", (1995) Cancer 76(4): 687-694						
EXAMI CONSI	INER DATE IDERED						
Tour	PX Hjmust 1/19/04						
EXAMI	INER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
	Respectfully submitted,						
	By:						

Linda O. Palladino
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



Att. Docket No.: REG 710-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

10/009,853

Applicant:

Papadopoulos, et al.

Date Filed:

December 6, 2001

MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMAÇOKINETIC

PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner:

Unknown

Group Art Unit:

1614

January 28, 2003

U.S. PATENT DOCUMENTS

Examiner **Initials**

Patent <u>Number</u> Issue Date **Publication**

Publication · Name

Number

Date

FOREIGN PATENT DOCUMENTS

Examiner Initials

Document Number

Date

Country

Class/ Date Subclass Yes

Translation

No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Davis-Smyth, T., et al., 1996, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction-cascade", The EMBO-Journal_15(18):4919-4927.

EXAMINER

DATE

CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and